NEW PUBLICATION: Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder

NEW PUBLICATION: Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder

Author: dev_scioto

Publications

Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder

In the News

Scioto Biosciences, Inc. Announces Top-Line Results of SB-121 in a Phase Ib Trial in Patients Diagnosed With Autism Spectrum Disorder

Press Release

Scioto Biosciences and Abigail Wexner Research Institute at Nationwide Children’s Hospital Receive a $2.3 Million Dollar Phase II SBIR Grant to Develop Novel Therapy

Press Release

Scioto Biosciences, Inc. Announces First Patient Dosed in Phase Ib Study in Patients Diagnosed with Autistic Disorder

Press Release

Scioto Biosciences Receives Series B Investment from Genome & Company

In the News

Learning New Tricks from Pathogenic Bacteria to Target the Microbiome

Press Release

Scioto Biosciences Presents Single-dose, Single Strain Pre-clinical C. diff Intervention at American Academy of Pediatrics National Conference & Exhibition

In the News

THE ROLE OF BIOFILMS: An Interview with Scioto Biosciences

In the News

Scioto Biosciences: Focused on Reducing Necrotizing Enterocolitis

In the News

A Better Way to Adminster Probiotics